Indeed, clinical data suggest reduced efficacy of aromatase inhibitors compared with fulvestrant in patients who have ESR1 mutations in the tumor or circulating tumor DNA (ctDNA) [103]. This evidence concerns the gene ESR1 and neoplasm.